查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1719131

披衣菌感染診斷市場－全球產業規模、佔有率、趨勢、機會和預測，按檢測類型、感染類型、最終用戶、地區和競爭情況分類，2020 年至 2030 年預測

Chlamydia Infection Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Type of Infections, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 184 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球衣原體感染診斷市值為 7.2133 億美元，預計到 2030 年將達到 10.3167 億美元，預測期內複合年成長率為 6.12%。沙眼衣原體是導致披衣菌感染的細菌，也是全球最常見的性傳染感染 (STI) 原因之一。由於披衣菌感染通常無症狀，因此經常無法確診，導致不孕症、骨盆腔發炎等併發症，並增加其他感染的易感性。隨著人們認知的提高和全球性傳染感染負擔的增加（尤其是 15 至 24 歲性活躍人群），對及時、準確診斷的需求也在增加。市場已採取技術創新來提高可及性和準確性，例如核酸擴增測試（NAAT），其高靈敏度已被認可。儘管依賴集中實驗室，但目前的努力重點是透過即時診斷技術提高檢測週轉率並擴大覆蓋範圍，支持更廣泛的公共衛生策略來控制感染。

市場概覽
預測期 2026-2030
2024年市場規模 7.2133億美元
2030年市場規模 10.3167億美元
2025-2030 年複合年成長率 6.12%
成長最快的領域 醫院
最大的市場 北美洲

關鍵市場促進因素

披衣菌感染盛行率上升推動披衣菌感染診斷市場發展

主要市場挑戰

診斷不足和缺乏認知

主要市場趨勢

技術進步

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球衣原體感染診斷市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依檢測類型（培養檢測、核酸擴增檢測（NAAT）、直接螢光抗體檢測、血清學檢測等）
    • 依感染類型（生殖器披衣菌感染、直腸披衣菌感染、眼部披衣菌感染）
    • 按最終使用者（醫院、專科診所、診斷中心）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖
    • 按測試類型
    • 按感染類型
    • 按最終用戶
    • 按地區

第6章：北美衣原體感染診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測

第7章：歐洲衣原體感染診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測

第8章：亞太地區衣原體感染診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測

第9章：南美衣原體感染診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測

第 10 章：中東和非洲衣原體感染診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第 13 章：競爭格局

  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Hologic, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc
  • Quidel Corporation
  • DiaSorin SpA
  • AstraZeneca
  • Teva Pharmaceutical Industries Limited
  • bioMerieux SA

第 14 章：策略建議

第15章調查會社について,免責事項

簡介目錄
Product Code: 15821

The Global Chlamydia Infection Diagnostics Market was valued at USD 721.33 million in 2024 and is projected to reach USD 1031.67 million by 2030, growing at a CAGR of 6.12% during the forecast period. Chlamydia trachomatis, the bacterium responsible for chlamydia infections, is one of the most widespread causes of sexually transmitted infections (STIs) globally. Due to its often asymptomatic nature, chlamydia frequently goes undiagnosed, leading to complications such as infertility, pelvic inflammatory disease, and increased vulnerability to other infections. As awareness grows and the global burden of STIs rises-particularly among sexually active individuals aged 15 to 24-demand for timely, accurate diagnostics has increased. The market has responded with technological innovations that enhance accessibility and accuracy, such as nucleic acid amplification tests (NAATs), which are recognized for their high sensitivity. Despite the reliance on centralized laboratories, ongoing efforts are focused on improving test turnaround and expanding reach through point-of-care technologies, supporting broader public health strategies to contain the infection.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 721.33 Million
Market Size 2030USD 1031.67 Million
CAGR 2025-20306.12%
Fastest Growing SegmentHospitals
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Chlamydia Infections is Driving Chlamydia Infection Diagnostics Market

The increasing global incidence of chlamydia infections is a major force behind the growth of the diagnostics market. As one of the most commonly reported STIs worldwide, chlamydia poses a significant health risk-particularly among adolescents and young adults who often lack awareness or access to regular testing. The asymptomatic nature of the infection makes it difficult to detect early, increasing the likelihood of long-term reproductive health complications such as infertility and ectopic pregnancies. The heightened focus on routine screening, particularly in high-risk populations, has accelerated the demand for diagnostic tools capable of delivering rapid, accurate results. This has led to the development and deployment of innovative testing methods, bolstering early intervention efforts and supporting global STI control initiatives. Educational campaigns and increased testing infrastructure are further reinforcing the demand for reliable chlamydia diagnostic solutions.

Key Market Challenges

Underdiagnosis and Lack of Awareness

A persistent challenge in the chlamydia diagnostics market is the widespread underdiagnosis of the infection, largely due to its asymptomatic presentation in the majority of cases. Without noticeable symptoms, many individuals remain unaware they are infected and do not seek testing, allowing the disease to spread undetected. This issue is compounded by limited public knowledge about STI risks, as well as cultural stigma surrounding sexual health, which deters open discussion and testing. In some regions, inadequate healthcare infrastructure and insufficient provider emphasis on STI screening further restrict access to diagnostics. These systemic and societal barriers contribute to a gap between infection rates and testing volumes, limiting early treatment and increasing the burden of long-term health complications.

Key Market Trends

Technological Advancements

Advancements in molecular diagnostics are significantly shaping the chlamydia diagnostics market. NAATs, including PCR and LAMP, have become the benchmark for detecting the genetic material of Chlamydia trachomatis, offering unparalleled sensitivity and specificity. These methods enable early detection, which is critical for timely treatment and preventing transmission. Furthermore, smartphone-integrated diagnostic platforms are emerging as accessible, user-friendly tools that facilitate at-home testing. These innovations empower individuals to screen for STIs with greater privacy and convenience. In parallel, serological and antibody-based assays are being utilized to detect historical infections, contributing to epidemiological tracking and broader public health insights. The integration of nucleic acid and serological tests is enhancing diagnostic capability, paving the way for more comprehensive infection profiling and treatment planning.

Key Market Players

  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Hologic, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc
  • Quidel Corporation
  • DiaSorin SpA
  • AstraZeneca
  • Teva Pharmaceutical Industries Limited
  • bioMerieux SA

Report Scope:

In this report, the Global Chlamydia Infection Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chlamydia Infection Diagnostics Market, By Test Type:

  • Culture Test
  • Nucleic Acid Amplification Test (NAAT)
  • Direct Fluorescent Antibody Test
  • Serology Test
  • Other

Chlamydia Infection Diagnostics Market, By Type of Infections:

  • Genital Chlamydia Infection
  • Rectal Chlamydia Infection
  • Ocular Chlamydia Infection

Chlamydia Infection Diagnostics Market, By End User:

  • Hospitals
  • Specialty Clinics
  • Diagnostics Centre

Chlamydia Infection Diagnostics Market, By Region:

  • North America
  • Asia-Pacific
  • Europe
  • Middle East & Africa
  • South America

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chlamydia Infection Diagnostics Market.

Available Customizations:

Global Chlamydia Infection Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chlamydia Infection Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Culture Test, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Test and Other)
    • 5.2.2. By Type of Infections (Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection)
    • 5.2.3. By End User (Hospitals, Specialty Clinics, Diagnostics Centre)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map
    • 5.3.1. By Test Type
    • 5.3.2. By Type of Infections
    • 5.3.3. By End User
    • 5.3.4. By Region

6. North America Chlamydia Infection Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Type of Infections
    • 6.2.3. By End User
    • 6.2.4. By Country
      • 6.2.4.1. United States Chlamydia Infection Diagnostics Market Outlook
        • 6.2.4.1.1. Market Size & Forecast
        • 6.2.4.1.1.1. By Value
        • 6.2.4.1.2. Market Share & Forecast
        • 6.2.4.1.2.1. By Test Type
        • 6.2.4.1.2.2. By Type of Infections
        • 6.2.4.1.2.3. By End User
      • 6.2.4.2. Canada Chlamydia Infection Diagnostics Market Outlook
        • 6.2.4.2.1. Market Size & Forecast
        • 6.2.4.2.1.1. By Value
        • 6.2.4.2.2. Market Share & Forecast
        • 6.2.4.2.2.1. By Test Type
        • 6.2.4.2.2.2. By Type of Infections
        • 6.2.4.2.2.3. By End User
      • 6.2.4.3. Mexico Chlamydia Infection Diagnostics Market Outlook
        • 6.2.4.3.1. Market Size & Forecast
        • 6.2.4.3.1.1. By Value
        • 6.2.4.3.2. Market Share & Forecast
        • 6.2.4.3.2.1. By Test
        • 6.2.4.3.2.2. By Type of Infections
        • 6.2.4.3.2.3. By End User

7. Europe Chlamydia Infection Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Type of Infections
    • 7.2.3. By End User
    • 7.2.4. By Country
      • 7.2.4.1. France Chlamydia Infection Diagnostics Market Outlook
        • 7.2.4.1.1. Market Size & Forecast
        • 7.2.4.1.1.1. By Value
        • 7.2.4.1.2. Market Share & Forecast
        • 7.2.4.1.2.1. By Test Type
        • 7.2.4.1.2.2. By Type of Infections
        • 7.2.4.1.2.3. By End User
      • 7.2.4.2. Germany Chlamydia Infection Diagnostics Market Outlook
        • 7.2.4.2.1. Market Size & Forecast
        • 7.2.4.2.1.1. By Value
        • 7.2.4.2.2. Market Share & Forecast
        • 7.2.4.2.2.1. By Test Type
        • 7.2.4.2.2.2. By Type of Infections
        • 7.2.4.2.2.3. By End User
      • 7.2.4.3. United Kingdom Chlamydia Infection Diagnostics Market Outlook
        • 7.2.4.3.1. Market Size & Forecast
        • 7.2.4.3.1.1. By Value
        • 7.2.4.3.2. Market Share & Forecast
        • 7.2.4.3.2.1. By Test Type
        • 7.2.4.3.2.2. By Type of Infections
        • 7.2.4.3.2.3. By End User
      • 7.2.4.4. Italy Chlamydia Infection Diagnostics Market Outlook
        • 7.2.4.4.1. Market Size & Forecast
        • 7.2.4.4.1.1. By Value
        • 7.2.4.4.2. Market Share & Forecast
        • 7.2.4.4.2.1. By Test Type
        • 7.2.4.4.2.2. By Type of Infections
        • 7.2.4.4.2.3. By End User
      • 7.2.4.5. Spain Chlamydia Infection Diagnostics Market Outlook
        • 7.2.4.5.1. Market Size & Forecast
        • 7.2.4.5.1.1. By Value
        • 7.2.4.5.2. Market Share & Forecast
        • 7.2.4.5.2.1. By Test Type
        • 7.2.4.5.2.2. By Type of Infections
        • 7.2.4.5.2.3. By End User

8. Asia Pacific Chlamydia Infection Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Type of Infections
    • 8.2.3. By End User
    • 8.2.4. By Country
      • 8.2.4.1. China Chlamydia Infection Diagnostics Market Outlook
        • 8.2.4.1.1. Market Size & Forecast
        • 8.2.4.1.1.1. By Value
        • 8.2.4.1.2. Market Share & Forecast
        • 8.2.4.1.2.1. By Test Type
        • 8.2.4.1.2.2. By Type of Infections
        • 8.2.4.1.2.3. By End User
      • 8.2.4.2. India Chlamydia Infection Diagnostics Market Outlook
        • 8.2.4.2.1. Market Size & Forecast
        • 8.2.4.2.1.1. By Value
        • 8.2.4.2.2. Market Share & Forecast
        • 8.2.4.2.2.1. By Test Type
        • 8.2.4.2.2.2. By Type of Infections
        • 8.2.4.2.2.3. By End User
      • 8.2.4.3. South Korea Chlamydia Infection Diagnostics Market Outlook
        • 8.2.4.3.1. Market Size & Forecast
        • 8.2.4.3.1.1. By Value
        • 8.2.4.3.2. Market Share & Forecast
        • 8.2.4.3.2.1. By Test Type
        • 8.2.4.3.2.2. By Type of Infections
        • 8.2.4.3.2.3. By End User
      • 8.2.4.4. Japan Chlamydia Infection Diagnostics Market Outlook
        • 8.2.4.4.1. Market Size & Forecast
        • 8.2.4.4.1.1. By Value
        • 8.2.4.4.2. Market Share & Forecast
        • 8.2.4.4.2.1. By Test Type
        • 8.2.4.4.2.2. By Type of Infections
        • 8.2.4.4.2.3. By End User
      • 8.2.4.5. Australia Chlamydia Infection Diagnostics Market Outlook
        • 8.2.4.5.1. Market Size & Forecast
        • 8.2.4.5.1.1. By Value
        • 8.2.4.5.2. Market Share & Forecast
        • 8.2.4.5.2.1. By Test Type
        • 8.2.4.5.2.2. By Type of Infections
        • 8.2.4.5.2.3. By End User

9. South America Chlamydia Infection Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Type of Infections
    • 9.2.3. By End User
    • 9.2.4. By Country
      • 9.2.4.1. Brazil Chlamydia Infection Diagnostics Market Outlook
        • 9.2.4.1.1. Market Size & Forecast
        • 9.2.4.1.1.1. By Value
        • 9.2.4.1.2. Market Share & Forecast
        • 9.2.4.1.2.1. By Test Type
        • 9.2.4.1.2.2. By Type of Infections
        • 9.2.4.1.2.3. By End User
      • 9.2.4.2. Argentina Chlamydia Infection Diagnostics Market Outlook
        • 9.2.4.2.1. Market Size & Forecast
        • 9.2.4.2.1.1. By Value
        • 9.2.4.2.2. Market Share & Forecast
        • 9.2.4.2.2.1. By Test Type
        • 9.2.4.2.2.2. By Type of Infections
        • 9.2.4.2.2.3. By End User
      • 9.2.4.3. Colombia Chlamydia Infection Diagnostics Market Outlook
        • 9.2.4.3.1. Market Size & Forecast
        • 9.2.4.3.1.1. By Value
        • 9.2.4.3.2. Market Share & Forecast
        • 9.2.4.3.2.1. By Test Type
        • 9.2.4.3.2.2. By Type of Infections
        • 9.2.4.3.2.3. By End User

10. Middle East & Africa Chlamydia Infection Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Type of Infections
    • 10.2.3. By End User
    • 10.2.4. By Country
      • 10.2.4.1. South Africa Chlamydia Infection Diagnostics Market Outlook
        • 10.2.4.1.1. Market Size & Forecast
        • 10.2.4.1.1.1. By Value
        • 10.2.4.1.2. Market Share & Forecast
        • 10.2.4.1.2.1. By Test Type
        • 10.2.4.1.2.2. By Type of Infections
        • 10.2.4.1.2.3. By End User
      • 10.2.4.2. Saudi Arabia Chlamydia Infection Diagnostics Market Outlook
        • 10.2.4.2.1. Market Size & Forecast
        • 10.2.4.2.1.1. By Value
        • 10.2.4.2.2. Market Share & Forecast
        • 10.2.4.2.2.1. By Test Type
        • 10.2.4.2.2.2. By Type of Infections
        • 10.2.4.2.2.3. By End User
      • 10.2.4.3. UAE Chlamydia Infection Diagnostics Market Outlook
        • 10.2.4.3.1. Market Size & Forecast
        • 10.2.4.3.1.1. By Value
        • 10.2.4.3.2. Market Share & Forecast
        • 10.2.4.3.2.1. By Test Type
        • 10.2.4.3.2.2. By Type of Infections
        • 10.2.4.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Competitive Landscape

  • 13.1. F. Hoffmann-La Roche Ltd.
  • 13.2. Abbott Laboratories
  • 13.3. Hologic, Inc.
  • 13.4. Becton, Dickinson and Company
  • 13.5. Bio-Rad Laboratories, Inc
  • 13.6. Quidel Corporation
  • 13.7. DiaSorin SpA
  • 13.8. AstraZeneca
  • 13.9. Teva Pharmaceutical Industries Limited
  • 13.10. bioMerieux SA

14. Strategic Recommendations

15. About us & Disclaimer